The latest longevity updates from our investment news desk.
CARMAT, the designer and developer of the world’s most advanced total artificial heart, has communicated its financial targets for the first time. The company expects sales of €10 to €13 million in 2023, and predicts achieving break-even by 2027.
In order to support a strong demand in Europe, and its commercial launch in the United States, anticipated in 2026, CARMAT has planned an ambitious industrial plan to increase manufacturing capacity.
“The last few months have been full of valuable learnings and have allowed us to fine-tune our market access and our industrial strategies,” said Stéphane Piat, Chief Executive Officer of CARMAT. “Given the progress made in various areas (commercial, manufacturing, quality, clinical, etc.), we are now in a position – for the first time – to communicate financial targets, and in particular revenue guidance of 10 to 13 million euros for 2023.”
Longeveron clinical trial
Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotech developing regenerative medicines for unmet medical needs, announced the publication of the full results from the company’s Phase 1 trial of Lomecel-B for hypoplastic left heart syndrome (HLHS).
“This data supports our conviction that Lomecel-B has the potential to alter the treatment landscape for patients with HLHS, a rare and life-threatening congenital heart disease,” said Chris Min, Longeveron’s Interim Chief Executive Officer and Chief Medical Officer. “Notably, the procedure appeared to be generally safe and well-tolerated in the babies undergoing heart surgery in the first 6 months of life. The study provisionally shows suggestions of possible improvement in measures of cardiac function, findings that are presently being tested in our ongoing controlled and randomized Phase 2 study.”
Longeveron is currently enrolling patients in the ELPIS II trial, a Phase 2a clinical trial intended to evaluate the safety and efficacy of intramyocardial injection of Lomecel-B in infants with HLHS.
Stay up-to-date with longevity investment news and trends on our dedicated investment portal.
NeuroSense clinical trial
NeuroSense Therapeutics (Nasdaq: NRSN), a company developing treatments for severe neurodegenerative diseases, announced final results from a biomarker study conducted to evaluate the potential of NeuroSense’s combination platform therapy for the treatment of Alzheimer’s disease. Preliminary results from the study, showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group. Based on these encouraging preliminary results, NeuroSense expanded the study with a larger healthy control group to further validate the results.
NeuroSense plans to commence a Phase 2 double-blind proof-of-concept study in Alzheimer’s disease in the first half of 2023.
Capsida appoints CFO
Gene therapy platform company Capsida Biotherapeutics announced the appointment of Julie Hakim as CFO. Hakim is a seasoned life sciences executive with more than 25 years’ experience shaping, scaling, and optimizing companies, accelerating both R&D and commercialisation, and paving the way for exponential growth at both large and small companies.
“In her very successful career as a financial executive, Julie has demonstrated expertise in many areas of finance and business – including R&D, product launches, revenue growth, acquisitions, integrations, and workforce expansions,” said Peter Anastasiou, Capsida’s CEO. “We are thrilled that Julie is joining Capsida as our CFO, where she will direct strategies that help us grow our business and help us unlock the potential of gene therapy for all patients.”